SCHEMBL20184099

SCHEMBL20184099

N#Cc1ccc2c(c1)C(=O)N(Cc1cccc(Oc3ccccc3)c1)C2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 3/20 0.43
HDAC1 Q13547 2/20 0.42
HDAC4 P56524 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
GRM5 P41594 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP2 O95551 1/20 0.39
TRPV6 Q9H1D0 1/20 0.38
NR3C1 P04150 1/20 0.38
PGR P06401 1/20 0.38
FAAH O00519 1/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20184005 0.88 ADAM17 (0.52) ADAM17KDM4EALDH1A1HPGDGAA
SCHEMBL20184098 0.87 HDAC1 (0.52) ADAM17HDAC1HDAC4HDAC6GRM5
SCHEMBL2021903 0.84 HDAC1 (0.51) ADAM17HDAC1KDM4EALDH1A1TDP1
SCHEMBL27923999 0.79 HDAC1 (0.48) HDAC1KDM4EALDH1A1GRM5FAAH
SCHEMBL1002813 0.78 GRM5 (0.58) HDAC1HDAC4HDAC6GRM5ROCK2
SCHEMBL20197547 0.75 ROCK2 (0.43) ADAM17HDAC1HDAC4HDAC6ALDH1A1
SCHEMBL20184092 0.73 ADAM17 (0.46) ADAM17HDAC1HDAC4HDAC6KDM4E
SCHEMBL17091283 0.72 PARP1 (0.46) SMN1; SMN2
SCHEMBL2028744 0.72 KMT2A (0.58) HDAC1HDAC4HDAC6KDM4EALDH1A1
SCHEMBL2021305 0.72 TNIK (0.56) HDAC1KDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357484-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-07-23 US disclosed
US-20190008836-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-01-10 US disclosed
EP-3327019-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10357484-B2 Heterocyclic compound HDAC1, HDAC11, HDAC5 ADAM17 2994/4885HDAC1 1/4885HDAC4 9/4885
US-20190008836-A1 HETEROCYCLIC COMPOUND HDAC1, HDAC11, HDAC5 ADAM17 2994/4885HDAC1 1/4885HDAC4 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.